BioLineRx (NASDAQ:BLRX) Stock Passes Above 200 Day Moving Average – Here’s What Happened

BioLineRx Ltd. (NASDAQ:BLRX)’s stock price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.87 and traded as high as $3.07. BioLineRx shares last traded at $2.98, with a volume of 7,371 shares traded.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioLineRx in a report on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

BioLineRx Stock Performance

The company has a market cap of $12.67 million, a P/E ratio of -1.51 and a beta of 1.55. The company’s 50-day moving average is $3.16 and its two-hundred day moving average is $2.87. The company has a quick ratio of 1.43, a current ratio of 1.58 and a debt-to-equity ratio of 0.16.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings data on Wednesday, May 27th. The biotechnology company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.68. BioLineRx had a negative return on equity of 37.73% and a negative net margin of 563.70%.The business had revenue of $0.48 million during the quarter, compared to analyst estimates of $0.34 million.

About BioLineRx

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.